Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
PCRX
Strong BuyFull HouseFLAGPacira BioSciences, Inc. · Healthcare · United States · $1.0B · Avg Vol: $16M/d
Pacira BioSciences depends heavily on a single long-acting local anaesthetic whose key patent protection was invalidated in litigation, opening the door to generic entry, and it carries convertible debt against that concentrated revenue base. That patent outcome is a specific, nameable adverse development. The strong momentum does not offset it, so this is a flag.
COMPANY DESCRIPTION
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing, commercializing, and manufacturing non-opioid pain management products, with its flagship EXPAREL providing long-acting local analgesia for postsurgical pain. The company benefits from its proprietary drug delivery technology, DepoFoam, and the strong market position of EXPAREL as a leading non-opioid solution, creating a significant competitive moat in the growing demand for opioid alternatives.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 666.8M | 675.0M | 701.0M | 726.4M | 2.9% | 746.2M | 752.9M | 788.2M | 4.2% |
| EPS | 0.35 | 0.91 | -2.15 | 0.16 | -23.0% | 0.35 | 0.17 | 0.21 | 14.1% |
| Shares | 45.9M | 46.5M | 46.2M | 41.1M | -10.5% | 39.9M | — | — | — |
| Debt | 763.4M | 586.0M | 638.9M | 418.2M | -18.2% | 412.1M | — | — | — |
| Equity | 775.0M | 870.1M | 778.3M | 693.1M | -3.7% | — | — | — | — |
| Op CF | 145.3M | 154.6M | 189.4M | 152.0M | 1.5% | 187.7M | — | — | — |
| Inv CF | -225.2M | 77.5M | -83.3M | 99.5M | — | — | — | — | — |
| Fin CF | -401.5M | -183.0M | 17.4M | -369.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PCRX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PCRX | Pacira BioSciences, Inc.(you) | $1.0B | 85 | Strong Buy |
| AMPH | Amphastar Pharmaceuticals, Inc. | $936M | 95 | Strong Buy |
| ANIP | ANI Pharmaceuticals, Inc. | $1.7B | 92 | Strong Buy |
| COLL | Collegium Pharmaceutical, Inc. | $786M | 72 | Buy |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.5B | 85 | Strong Buy |
| GTII.CN | Green Thumb Industries Inc. | $1.6B | 94 | Strong Buy |
| PAHC | Phibro Animal Health Corporation | $1.5B | 74 | Buy |
| TRLV | Trulieve Cannabis Corp. | $2.3B | 90 | Strong Buy |
| ETON | Eton Pharmaceuticals, Inc. | $1.7B | 72 | Buy |
| IRWD | Ironwood Pharmaceuticals, Inc. | $682M | 100 | Strong Buy |
Peer medians: ROE -30.8% · P/E 26.9x · Gross margin 58.1%